Primmune Therapeutics
Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.
Domain
primmunerx.com
Country
United StatesIndustry
BiotechnologyEmployees
1-10
Last Funding
$23.3M
Founded
2016
Tech Stack (25 technologies)
Frequently Asked Questions
What technologies does Primmune Therapeutics use?+
Primmune Therapeutics uses 25 technologies including Contact Form 7, Google Analytics, Google Tag Manager.
What industry is Primmune Therapeutics in?+
Primmune Therapeutics operates in the Biotechnology industry.
Where is Primmune Therapeutics based?+
Primmune Therapeutics is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026